Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Shilpa Medicare Limited is active in the Biotechnology and Pharmaceuticals technology area with 2 pending office actions. These actions are distributed between 2 distinct examiners, providing perspectives from different reviewers at the USPTO. Both pending matters are located within 1 distinct art unit, suggesting a technical focus for these pharmaceutical filings. The presence of 2 pending office actions in a single art unit indicates that the company is pursuing multiple related innovations within a specific technical niche.
The busiest examiner, HASTINGS, ALISON AZAR, is responsible for 1 pending office action. With the 2 pending office actions distributed among 2 distinct examiners, the workload is split. This distribution requires the company to manage two different examiner styles within the same art unit. Practitioners should ensure that arguments made to one examiner are consistent with those presented to the other to maintain a cohesive strategy across the Biotechnology and Pharmaceuticals portfolio. By engaging with 2 distinct examiners, the company reduces the risk that a single examiner's interpretation will impact the entire active portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HASTINGS, ALISON AZAR | 1 | 63.5% | +40.2% |
| PHAN, DOAN THI-THUC | 1 | 42.7% | +47.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18905163 | APIXABAN ORAL LIQUID DOSAGE FORMS | HASTINGS, ALISON AZAR | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18905163 | APIXABAN ORAL LIQUID DOSAGE FORMS | HASTINGS, ALISON AZAR | — |
| 18887827 | TRANEXAMIC ACID SPRAY FOR KNEE ARTHROPLASTY | PHAN, DOAN THI-THUC | — |
| Art Unit | Apps |
|---|---|
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18905163 | APIXABAN ORAL LIQUID DOSAGE FORMS | HASTINGS, ALISON AZAR | — | §103§112 | Non-Final OA | — | Pending | Oct 03, 2024 |
| 18887827 | TRANEXAMIC ACID SPRAY FOR KNEE ARTHROPLASTY | PHAN, DOAN THI-THUC | 1613 | §102§103§112DP | Non-Final OA | — | Pending | Sep 17, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial